A key feature of osteoarthritis (OA) is the erosion of articular cartilage, which is caused by degradative proteinases, such as matrix metalloproteinases (MMPs) and aggrecanases, which are produced abnormally by certain OA chondrocytes. Chondrocyte-dependent matrix-degrading activities lie at the heart of OA pathology and prevention may halt or slow down the inevitable progression of OA. This project will concentrate on the regulation of the gene encoding the major collagenase involved in OA, namely MMP-13. In vivo, gene expression is not only controlled by transcriptional activators and repressors, but also depends on the epigenetic DNA methylation of the promoter, which is the mechanism whereby genes that are never expressed by a somatic cell are permanently silenced. This study will be the first to take into account the DNA methylation status of the MMP-13 promoter to investigate regulation of expression of this gene in a manner that replicates what takes place in vivo. We will test the following hypothesis: MMP-13 promoter activity is determined by the interactions between DNA methylation status and transcription factor binding to cognate binding sites. Thus, the presence of methylation correlates, on the whole, with gene silencing by preventing the binding of some transcription factors.
Specific aims are: 1) Determine the methylation status of all 14 CpG sites in the MMP-13 promoter in chondrocytes derived from non-OA, superficial and deep zones of OA patients, quantify mRNA expression and % methylation for selected CpG sites. 2) Investigate the effects of inflammatory cytokines and a demethylation agent on MMP-13 expression and methylation status. 3) Compare the effects of transcription factors on MMP-13 promoter activity in non-methylated and methylated promoter constructs. 4) Investigate specific binding of transcription factors to the MMP-13 promoter in normal vs cytokine-induced chondrocytes. After providing complete in vivo data regarding the changes in methylation status in OA, we will determine how the methylation status of normal chondrocytes is changed by inflammatory cytokines. Our sub-hypothesis is that these cytokines will initiate a demethylation of the MMP-13 promoter, thereby increasing accessibility to transcription factors and thus transcription of MMP-13. In the promoter construct studies, we will focus initially on transcription factors that are known to regulate MMP-13 promoter activity, including ETS factors, AP-1, Runx2 and NFkB. Our sub- hypothesis is that DNA methylation will prevent binding of some, but not all, transcription factors. We will then investigate which transcription factors are actually bound to the MMP-13 promoters in MMP-13 expressing vs non-expressing cells in cotransfections using non-methylated and methylated MMP-13 promoter constructs and in EMSA and ChIP assays. This will allow us to correlate functional responses with the proximity of CpG sites and methylation status. The first two aims will be investigated by the Co-PI in Southampton, where previous experience in the techniques exists. The second two aims build on the experience of the PI with respect to the transcriptional regulation. Previous findings by the Southampton group indicate that demethylation underlies the abnormal MMP-13 expression in OA. The proposed studies will advance considerably our understanding about the importance of DNA methylation in the pathology of OA. ? ? ? ? ? ?
|Otero, Miguel; Peng, Haibing; Hachem, Karim El et al. (2017) ELF3 modulates type II collagen gene (COL2A1) transcription in chondrocytes by inhibiting SOX9-CBP/p300-driven histone acetyltransferase activity. Connect Tissue Res 58:15-26|
|Takahashi, Atsushi; de Andrés, María C; Hashimoto, Ko et al. (2017) DNA methylation of the RUNX2 P1 promoter mediates MMP13 transcription in chondrocytes. Sci Rep 7:7771|
|Imagawa, Kei; de Andrés, María C; Hashimoto, Ko et al. (2014) Association of reduced type IX collagen gene expression in human osteoarthritic chondrocytes with epigenetic silencing by DNA hypermethylation. Arthritis Rheumatol 66:3040-51|
|Ritter, Susan Y; Subbaiah, Roopashree; Bebek, Gurkan et al. (2013) Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues. Arthritis Rheum 65:981-92|
|de Andrés, María C; Imagawa, Kei; Hashimoto, Ko et al. (2013) Loss of methylation in CpG sites in the NF-?B enhancer elements of inducible nitric oxide synthase is responsible for gene induction in human articular chondrocytes. Arthritis Rheum 65:732-42|
|Hashimoto, Ko; Otero, Miguel; Imagawa, Kei et al. (2013) Regulated transcription of human matrix metalloproteinase 13 (MMP13) and interleukin-1? (IL1B) genes in chondrocytes depends on methylation of specific proximal promoter CpG sites. J Biol Chem 288:10061-72|
|Otero, Miguel; Plumb, Darren A; Tsuchimochi, Kaneyuki et al. (2012) E74-like factor 3 (ELF3) impacts on matrix metalloproteinase 13 (MMP13) transcriptional control in articular chondrocytes under proinflammatory stress. J Biol Chem 287:3559-72|
|Otero, Miguel; Favero, Marta; Dragomir, Cecilia et al. (2012) Human chondrocyte cultures as models of cartilage-specific gene regulation. Methods Mol Biol 806:301-36|
|Goldring, Mary B (2012) Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in health and osteoarthritis. Ther Adv Musculoskelet Dis 4:269-85|
|Goldring, Mary B; Marcu, Kenneth B (2012) Epigenomic and microRNA-mediated regulation in cartilage development, homeostasis, and osteoarthritis. Trends Mol Med 18:109-18|
Showing the most recent 10 out of 17 publications